Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5081232 | 0.95 | POLB (0.32) | POLBGAACYP2C19MRGPRX4 | |
| Hydrochloric Acid SCHEMBL399507 | 0.93 | MRGPRX4 (0.32) | MRGPRX4 | |
| Hydrochloric Acid SCHEMBL5084196 | 0.92 | POLB (0.30) | POLBGAACYP2C19 | |
| Bromide SCHEMBL5083994 | 0.91 | MRGPRX4 (0.32) | MRGPRX4 | |
| Hydrochloric Acid SCHEMBL5083581 | 0.91 | — | — | |
| Hydrochloric Acid SCHEMBL5077723 | 0.87 | POLB (0.32) | POLBGAACYP2C19 | |
| Hydrochloric Acid SCHEMBL8511528 | 0.86 | OPRD1 (0.31) | — | |
| Hydrochloric Acid SCHEMBL5080404 | 0.86 | MAPT (0.35) | — | |
| Hydrochloric Acid SCHEMBL5083528 | 0.85 | — | — | |
| Hydrochloric Acid SCHEMBL5077685 | 0.85 | ALDH1A1 (0.31) | MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2511305-A1 | Bridged metallocene compound for olefin polymerization and method of polymerizing olefin using the same | Mitsui Chemicals, Inc. (JP) | 2012-10-17 | — | — | EP | disclosed |
| EP-2465878-A1 | Bridged metallocene compound for olefin polymerization and method of polymerizing olefin using the same | Mitsui Chemicals, Inc. (JP) | 2012-06-20 | — | — | EP | disclosed |
| EP-2465879-A1 | Bridged metallocene compound for olefin polymerization and method of polymerizing olefin using the same | Mitsui Chemicals, Inc. (JP) | 2012-06-20 | — | — | EP | disclosed |
| US-7393965-B2 | Crosslinked metallocene compound for olefin polymerization and method of polymerizing olefin with the same | MITSUI CHEMICALS, INC. (JP) | 2008-07-01 | — | — | US | disclosed |
| US-20060161013-A1 | Crosslinked metallocene compound for olefin polymerization and method of polymerizing olefin with the same | MITSUI CHEMICALS, INC. (JP) | 2006-07-20 | — | — | US | disclosed |
| EP-1548018-A1 | CROSSLINKED METALLOCENE COMPOUND FOR OLEFIN POLYMERIZATION AND METHOD OF POLYMERIZING OLEFIN WITH THE SAME | Mitsui Chemicals, Inc. (JP) | 2005-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060161013-A1 | Crosslinked metallocene compound for olefin polymerization and method of polymerizing olefin with the same | PCNA, MACF1, PIN1 | POLB 233/4885GAA 4028/4885CYP2C19 1376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.